


ICAHN STROKE NEWSLETTER

March is Brain Injury Awareness Month



Food for thought:

- 80% of stroke patients survive their stroke and live with leftover disability
- Stroke is STILL the #1 cause of disability in the US
- As a nation, in 2018 we treated 100,000 patients with Activase, roughly a 12% treatment rate, and even less with thrombectomy



Dates to Remember:

- March 12
SSEO
Teleconference
Series: Psychological Effects of Stroke
Featuring Mary F. Schmidt, PhD, Neuropsychologist.
[Click here](#) for more information.
- March 15
Last day to sign the GWTG Stipend ICAHN Agreement
- Be sure to update GWTG by the 15th of every month

Watch for This!

- The ICAHN Stroke Library has been updated.
[Click here](#) to check out the plethora of resources!

Two things you can implement in 2019:

Help ensure that all eligible stroke patients receive medical or mechanical intervention to reduce disability by...

1. Adding formal Individual Disability Assessment to your protocol. Hospitals across the country are now adding check boxes to their EMR to ensure that practitioners have engaged the patient on how they will be impacted by their deficits and must select: disabling or non-disabling
2. Providing feedback to your ED physicians and nurses on how patients did after leaving the ED (not just patients treated with Activase or thrombectomy, but all stroke patients. It is so valuable for your front-line team to know their patients' outcomes such as discharge status, Modified Rankin at 90 days, etc.

The above message is provided by Anne Schutt from Genentech

Introducing Target: Stroke Phase 3!

Join us for the Launch Webinar on April 29, 2019 12-1 pm (CST)/1-2 pm (EST)

Target: Stroke has helped hospitals nationwide achieve improved stroke outcomes through reduced door-to-needle (DTN) times for eligible ischemic stroke patients. Phase III of this American Heart Association/American Stroke Association initiative further raises the bar by setting more aggressive targets for timely treatment with IV alteplase. The new phase also adds a second type of intervention into the mix, setting the first-ever targets for prompt treatment with endovascular therapy (EVT).

Join us as Dr. Lee Schwamm and Dr. Eric Smith overview the launch of Target: Stroke Phase III.

This webinar will address the following:

- Phase III program goals
- New targets for door-to-needle (DTN) times in eligible ischemic stroke patients.
- Introduce targets for door-to-device (DTD) times in acute ischemic stroke patients treated with endovascular therapy (EVT)
- New recognition levels and criteria

Find more information on Target: Stroke and Phase 3 by clicking below!

Questions? Contact:
Trudi Colby, BSN, RN
tcolby@icahn.org or
815.303.4069



TIME LOST IS BRAIN LOST.
Learn more at Stroke.org/TargetStroke.



Genentech is a National Supporter of the American Heart Association's Target Stroke - PI